HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53

British Journal of Cancer

Volumn 112, Issue 8, 2015, Pages 1358-1366

  Meulendijks, D ^a   Tomasoa, N B ^a   Dewit, L ^a   Smits, P H M ^b   Bakker, R ^b   Van Velthuysen, M L F ^a   Rosenberg, E H ^a   Beijnen, J H ^a,c   Schellens, J H M ^a,c   Cats, A ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

anal canal carcinoma; chemoradiotherapy; human papillomavirus; p16; p53

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE; MITOMYCIN; PROTEIN P16; PROTEIN P53; CYCLIN DEPENDENT KINASE INHIBITOR 2A; TP53 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ANAL CANAL SQUAMOUS CELL CARCINOMA; ANUS CARCINOMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CHEMORADIOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE CONTROL; EXON; FEMALE; FOLLOW UP; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROTEIN EXPRESSION; SEX DIFFERENCE; SQUAMOUS CELL CARCINOMA; TREATMENT FAILURE; ALPHAPAPILLOMAVIRUS; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CLASSIFICATION; DRUG THERAPY; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MIDDLE AGED; MUTATION; RADIOTHERAPY; TREATMENT OUTCOME; VERY ELDERLY; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; ALPHAPAPILLOMAVIRUS; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DRUG THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PAPILLOMAVIRUS INFECTIONS; RADIOTHERAPY; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84928143287     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.20     Document Type: Article

References (36)

1. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie T-X, Zhang J, Wang J, Zhang N, El-Naggar AK, Jasser SA, Weinstein JN, Trevinõ L, Drummond JA, Muzny DM, Wu Y, Wood LD, Hruban RH, Westra WH, Koch WM, Califano JA, Gibbs RA, Sidransky D, Vogelstein B, Velculescu VE, Papadopoulos N, Wheeler DA, Kinzler KW, Myers JN (2011) Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333: 1154-1157.
2. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG (2010) Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer 116: 4007-4013.
3. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363: 24-35.
4. Boyle JO, Hakim J, Koch W, van der Riet P, Hruban RH, Roa RA, Correo R, Eby YJ, Ruppert JM, Sidransky D (1993) The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 53: 4477-4480.
5. Braakhuis BJM, Snijders PJF, Keune W-JH, CJLM Meijer, Ruijter-Schippers HJ, Leemans CR, Brakenhoff RH (2004) Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst 96: 998-1006.
6. Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, Carter JJ, Porter PL, Galloway DA, McDougall JK (2004) Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 101: 270-280.
7. Deutsch E, Lemanski C, Pignon JP, Levy A, Delarochefordiere A, Martel-Lafay I, Rio E, Malka D, Conroy T, Miglianico L, Becouarn Y, Malekzadeh K, Paris E, Juzyna B, Ezra P, Azria D (2013) Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial. Ann Oncol 24: 2834-2838.
8. Gilbert DC, Williams A, Allan K, Stokoe J, Jackson T, Linsdall S, Bailey CM, Summers J (2013) p16(INK4A), p53, EGFR expression and KRAS mutation status in squamous cell cancers of the anus: Correlation with outcomes following chemo-radiotherapy. Radiother Oncol 109: 146-151.
9. Harima Y, Sawada S, Nagata K, Sougawa M, Ohnishi T (2002) Human papilloma virus (HPV) DNA associated with prognosis of cervical cancer after radiotherapy. Int J Radiat Oncol Biol Phys 52: 1345-1351.
10. Hoots BE, Palefsky JM, Pimenta JM, Smith JS (2009) Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 124: 2375-2383.
11. James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, Maughan T, McDonald A, Essapen S, Leslie M, Falk S, Wilson C, Gollins S, Begum R, Ledermann J, Kadalayil L, Sebag-Montefiore D (2013) Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2-2 factorial trial. Lancet Oncol 14: 516-524.
12. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C (2003) Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 100(14): 8424-8429.
13. Kim S, Jary M, Mansi L, Benzidane B, Cazorla A, Demarchi M, Nguyen T, Kaliski A, Delabrousse E, Bonnetain F, Letondal P, Bosset JF, Valmary-Degano S, Borg C (2013) DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma. Ann Oncol 24(12): 3045-3050.
14. Kimple RJ, Smith MA, Blitzer GC, Torres AD, Martin JA, Yang RZ, Peet CR, Lorenz LD, Nickel KP, Klingelhutz AJ, Lambert PF, Harari PM (2013) Enhanced radiation sensitivity in HPV-positive head and neck cancer. Cancer Res 73: 4791-4800.
15. Kleter B, van Doorn LJ, Schrauwen L, Molijn A, Sastrowijoto S, ter Schegget J, Lindeman J, ter Harmsel B, Burger M, Quint W (1999) Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 37: 2508-2517.
16. Lampejo T, Kavanagh D, Clark J, Goldin R, Osborn M, Ziprin P, Cleator S (2010) Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review. Br J Cancer 103: 1858-1869.
17. Lechner M, Frampton GM, Fenton T, Feber A, Palmer G, Jay A, Pillay N, Forster M, Cronin MT, Lipson D, Miller Va, Brennan Ta, Henderson S, Vaz F, O'Flynn P, Kalavrezos N, Yelensky R, Beck S, Stephens PJ, Boshoff C (2013) Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV\+ and HPV-tumors. Genome Med 5: 49.
18. Lu C, El-Deiry WS (2009) Targeting p53 for enhanced radio-and chemosensitivity. Apoptosis 14: 597-606.
19. Meulendijks D, Dewit L, Tomasoa NB, van Tinteren H, Beijnen JH, Schellens JHM, Cats A (2014) Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. Br J Cancer 111(9): 1726-1733.
20. Milas L, Fang F-M, Mason Ka, Valdecanas D, Hunter N, Koto M, Ang KK (2007) Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation. Int J Radiat Oncol Biol Phys 67: 568-572.
21. Nees M, Homann N, Discher H, Andl T, Enders C, Herold-Mende C, Schuhmann A, Bosch FX (1993) Expression of mutated p53 occurs in tumor-distant epithelia of head and neck cancer patients: a possible molecular basis for the development of multiple tumors. Cancer Res 53: 4189-4196.
22. Nelson RA, Levine AM, Bernstein L, Smith DD, Lai LL (2013) Changing patterns of anal canal carcinoma in the United States. J Clin Oncol 31: 1569-1575.
23. Netherlands Cancer Registry. Available at: http://www.cijfersoverkanker.nl/(last accessed 14 August 2013).
24. Olivatto LO, Vieira FM, Pereira BV, Victorino AP, Bezerra M, Araujo CM, Erlich F, Faroni L, Castro L, Lusis EC, Marins A, Ferreira CG (2013) Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. Cancer 119: 2973-2980.
25. Rietbergen MM, Snijders PJF, Beekzada D, Braakhuis BJM, Brink A, Heideman DAM, Hesselink AT, Witte BI, Bloemena E, Baatenburg-De Jong RJ, René Leemans C, Brakenhoff RH (2014) Molecular characterization of p16-immunopositive but HPV DNA-negative oropharyngeal carcinomas. Int J Cancer 134(10): 2366-2372.
26. Rödel F, Wieland U, Fraunholz I, Kitz J, Rave-Fränk M, Wolff Ha, Weiss C, Wirtz R, Balermpas P, Fokas E, Rödel C (2014) Human papillomavirus DNA load and p16(INK4a) expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy. Int J Cancer 136(2): 278-288.
27. Serup-Hansen E, Linnemann D, Skovrider-Ruminski W, Hogdall E, Geertsen PF, Havsteen H (2014) Human papillomavirus genotyping and p16 expression as prognostic factors for patients with american joint committee on cancer stages I to III carcinoma of the anal canal. J Clin Oncol 32(17): 1812-1817.
28. Skinner HD, Sandulache VC, Ow TJ, Meyn RE, Yordy JS, Beadle BM, Fitzgerald AL, Giri U, Ang KK, Myers JN (2012) TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res 18: 290-300.
29. Smeets SJ, Braakhuis BJM, Abbas S, Snijders PJF, Ylstra B, van de Wiel MA, Meijer GA, Leemans CR, Brakenhoff RH (2006) Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene 25: 2558-2564.
30. Stengel A, Schnittger S, Weissmann S, Kuznia S, Kern W, Kohlmann A, Haferlach T, Haferlach C (2014) TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy and a poor prognosis. Blood 124: 251-258.
31. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, Carter SL, Voet D, Cortés ML, Auclair D, Berger MF, Saksena G, Guiducci C, Onofrio RC, Parkin M, Romkes M, Weissfeld JL, Seethala RR, Wang L, Rangel-Escarenõ C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Winckler W, Ardlie K, Gabriel SB, Meyerson M, Lander ES, Getz G, Golub TR, Garraway La, Grandis JR (2011) The mutational landscape of head and neck squamous cell carcinoma. Science 333: 1157-1160.
32. Tandon S, Tudur-Smith C, Riley RD, Boyd MT, Jones TM (2010) A systematic review of p53 as a prognostic factor of survival in squamous cell carcinoma of the four main anatomical subsites of the head and neck. Cancer Epidemiol Biomarkers Prev 19: 574-587.
33. Valmary-Degano S, Jacquin E, Prétet J-L, Monnien F, Girardo B, Arbez-Gindre F, Joly M, Bosset J-F, Kantelip B, Mougin C (2013) Signature patterns of human papillomavirus type 16 in invasive anal carcinoma. Hum Pathol 44: 992-1002.
34. Westra WH, Taube JM, Poeta ML, Begum S, Sidransky D, Koch WM (2008) Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res 14: 366-369.
35. Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks Ma, Shih IM, Kurman RJ (2011) Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol 24: 1248-1253.
36. Yhim H-Y, Lee N-R, Song E-K, Kwak J-Y, Lee ST, Kim JH, Kim J-S, Park HS, Chung I-J, Shim H-J, Hwang J-E, Kim HR, Nam T-K, Park M-R, Shim H, Park HS, Kim HS, Yim C-Y (2011) The prognostic significance of tumor human papillomavirus status for patients with anal squamous cell carcinoma treated with combined chemoradiotherapy. Int J Cancer 129: 1752-1760.